Evodia rutaecarpa (Juss.) Benth is a traditional Chinese medicine. The active ingredient, evodiamine, is a quinolone alkaloid and is found in Evodiae fructus. We investigated the effect of evodiamine on atherosclerosis using LDLR−/− mice fed on a high-fat diet and ox-LDL-induced MOVAS cell lines to construct mouse models and cell-line models. We report a significant reduction in atherosclerotic plaque formation in mice exposed to evodiamine. Our mechanistic studies have revealled that evodiamine can regulate the proliferation, migration, and inflammatory response of and oxidative stress in vascular smooth muscle cells by inhibiting the activation of the PI3K/Akt axis, thus inhibiting the occurrence and development of atherosclerosis. In conclusion, our findings reveal a role for evodiamine in the regulation of vascular smooth muscle cells in atherosclerosis, highlighting a potential future role for the compound as an anti-atherosclerotic agent.
Background: High levels of apolipoprotein C3 (APOC3) can lead to hypertriglyceridemia, which increases the risk of cardiovascular disease. We aim to create APOC3 knockout (KO) rabbits and explore the effects of APOC3 deletion on the occurrence and development of atherosclerosis.Methods: A sgRNA anchored to exon 2 of APOC3 was designed to edit embryos using the CRISPR/Cas9 system. The founder rabbits were sequenced, and their lipid profile, inflammatory cytokines and atherosclerotic plaques were analyzed.Results: When given a normal chow (NC) diet, all APOC3 KO rabbits had low plasma TG level, which was two times lower than that of the matched age control group. Additionally, their plasma lipoprotein lipase (LPL) increased. When fed a high-fat diet (HFD), it was observed that APOC3 deficiency was more conducive to the maintenance of plasma TG, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels in rabbits, the inhibition of inflammatory response and the protection of atherosclerosis in rabbits.Conclusion: APOC3 KO rabbit models can be obtained with the CRISPR/Cas9 system to combat the formation of HFD-induced atherosclerosis, indicating a novel therapeutic target to treat atherosclerosis.